Eisai Announces Investigational Data Highlighting LENVIMA® (lenvatinib) Based Combination Therapy in Patients With Renal Cell Carcinoma at IKCS 2020

WOODCLIFF LAKE, N.J., Nov. 5, 2020 /PRNewswire/ -- Eisai will present seven abstracts at the International Kidney Cancer Symposium (IKCS) 2020 from November 6-7, 2020. New investigational data from Study 218, a Phase 2 trial evaluating the safety and efficacy of two starting doses (14 mg...

from PR Newswire: https://ift.tt/353fGLH